José Salvador Rodrigues de Oliveira

Outcome predictors of 84 patients with hematologic malignancies and <i>Fusarium</i> infection

Márcio Nucci, Elias Anaissie, Flávio Queiroz‐Telles et al. · Cancer · 2003 · 302 citations · Full text

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · The Lancet Oncology · 2021 · 245 citations

Interim Analysis, Lymphoid Neoplasia, Medicine +8

Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.

Valéria C.C. Andrade, André L. Vettore, R Felix et al. · PubMed · 2008 · 118 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Cancer Immunosurveillance +14

Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia

Leonardo Javier Arcuri, Samir Nabhan, Renato Cunha et al. · Biology of Blood and Marrow Transplantation · 2020 · 44 citations

Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial

Jörge E. Cortes, Cármino Antônio De Souza, Manuel Ayala et al. · The Lancet Haematology · 2016 · 40 citations · Full text

Chronic Phase, Open-label Trial, Hematological Malignancy +11